Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer
1 other identifier
observational
300
1 country
1
Brief Summary
This study aimed to compare the activity of Thymidine Kinase 1 in serum of two groups of woman at high and normal risk for breast/ovary cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2009
CompletedStudy Start
First participant enrolled
March 1, 2009
CompletedFirst Posted
Study publicly available on registry
March 5, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2011
CompletedJune 3, 2010
March 1, 2009
1 year
February 22, 2009
June 2, 2010
Conditions
Keywords
Study Arms (2)
1
With BRCA1 or BRCA2 mutations
2
Without BRCA1 or BRCA2 mutations
Eligibility Criteria
women visiting the outpatient oncology clinic for genetic/familial high-risk assessments
You may qualify if:
- women from family with more than two breast cancer cases and one or more cases of ovarian cancer diagnosed at any age;
- women from family with more than three breast cancer cases diagnosed before the age 50;
- women from family withsister pair in which one of the following combinations was diagnosed before the age of 50: two breast cancers, two ovarian cancers, or a breast and ovarian cancer.
You may not qualify if:
- pregnant women;
- women with generalized CMV and HZV infections;
- women with severe B12 deficiency and megaloblastic anaemia;
- women with severe rheumatoid arthritis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hadassah Medical Organization
Jerusalem, 91120, Israel
Related Publications (1)
Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
PMID: 23966579DERIVED
Biospecimen
Serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 22, 2009
First Posted
March 5, 2009
Study Start
March 1, 2009
Primary Completion
March 1, 2010
Study Completion
March 1, 2011
Last Updated
June 3, 2010
Record last verified: 2009-03